Fosun Pharma (02196) Completes Issuance of First Tranche of 2026 Scientific and Technological Innovation Bonds

Bulletin Express
Feb 03

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Stock Code: 02196) recently completed the issuance of its first tranche of 2026 scientific and technological innovation bonds under a RMB4 billion registered program. The new bonds have a total principal of RMB1 billion, a two-year term, and a coupon rate of 2.4%. The value date is set at 2 February 2026, with a payment date of 2 February 2028.

China Merchants Bank Co., Ltd. acted as the leading underwriter, with Bank of Beijing Co., Ltd., Shanghai Pudong Development Bank Co., Ltd., China Everbright Bank Company Limited, and HUA XIA BANK CO., Limited serving as joint leading underwriters. Relevant issuance documents are available on the websites of China Money and the Shanghai Clearing House.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10